Healthcare Industry News: Atrial Septal Defect
News Release - July 6, 2020
NuVera Announces Successful First-in-Human Use of NuVision(TM) ICE CatheterOne of first virtually-supported clinical study cases performed during world pandemic
LOS GATOS, Calif., July 6, 2020 -- (Healthcare Sales & Marketing Network) -- NuVera Medical Inc. (NuVera), a portfolio company of Shifamed LLC, focused on enabling a new era in transcatheter cardiac interventions through the advancement of real-time 3D intracardiac echocardiography (4D ICE), announced today initiation of the company's first-in-human clinical trial to evaluate the performance of its novel NuVision™ ICE Catheter. The first study participant was successfully treated this month for an Atrial Septal Defect by principal investigator Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay, using remote, live-feed support from the NuVera team who were located in the U.S.
"I am extremely pleased to be part of the first use of this technology. Typically, a case involving a septal defect would require general anesthesia and a separate sonographer to perform transesophageal imaging," stated Dr. Ebner. "With the NuVision ICE Catheter we were able to perform the procedure with virtual support from NuVera with the patient under conscious sedation. Viewing the intracardiac structures and leaflets from this perspective was entirely new, enabling a much more simplified septal repair procedure. The patient was discharged the next morning without any excess swelling from the use of TEE."
NuVera's novel NuVision ICE Catheter is designed to offer interventional cardiologists and electrophysiologists rapid, real-time 3D, multi-planar insights into structural heart and cardiac ablation procedures, which are difficult to detect with current technology and may require general anesthesia. The wide, 90° x 90° view of the cardiac anatomy provided by the technology has the potential to better guide complex cardiac procedures, improve outcomes and reduce procedure times while lowering healthcare costs.
"Today marks a major milestone in the history of NuVera as we transition to a clinical-stage company," Todor Jeliaskov, CEO of NuVera Medical. "I am incredibly grateful to Dr. Ebner and the entire clinical team for their flawless performance and for trusting the NuVera team to remotely support the first human case. We see tremendous potential for the NuVision ICE Catheter to transform complex cardiac procedures and look forward to bringing this beneficial technology to market."
About NuVera Medical Inc.
NuVera Medical is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical innovation hub. The company is developing the NuVision ICE Catheter to enable a new era in transcatheter cardiac interventions through the advancement of real-time 3D intracardiac echocardiography (4D ICE). To learn more about NuVera Medical, please visit www.nuveramedical.com.
About Shifamed LLC
Founded by serial entrepreneur Amr Salahieh, Shifamed LLC is a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.
Source: NuVera Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.